Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
Aims: adaptation and validation of the ELISA method insulin glargine determination for the pharmacokinetic study, practical approval in the biosimilars clinical trial.Materials and methods. Serum insulin glargine determination was measured using a commercial ELISA kit. All tests were run on a Person...
Guardado en:
Autores principales: | L. N. Shitov, Yu. A. Dzhurko, R. V. Drai, I. E. Makarenko, A. L. Khokhlov, L. A. Khozova, O. V. Afonkina, Yu. A. Sevastyanova, N. A. Vasilenko, A. A. Abramova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a41eb306288644d4abb8cd179e27d865 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
por: Alexander Y. Mayorov, et al.
Publicado: (2020) -
rDNA insulin glargine U300 – a critical appraisal
por: Wang F, et al.
Publicado: (2016) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan TJE, et al.
Publicado: (2021)